|
⚲
|
| Keyboard |
| Oncogenex Pharmaceuticals Inc | |
|---|---|
| Ticker | ACHV |
| CIK # | 0000949858 |
| CUSIP | 004468500 |
| Sector | Life Sciences - In Vitro & In Vivo Diagnostic Substances |
| Address | 1522 217th Place SE, Bothell, WA 98021 |
| Source | [EDGAR] |
| Reg D Offering (Form D) | Filed | Raised | Terms |
|---|---|---|---|
| Achieve Life Sciences Inc | 2022-11-29 | 18.9 M | Exemption: 506(b) · Remaining: $6,100,000 · Duration: One year or less · Finder's Fee: $756,000 · Revenue: Decline to Disclose |
| Oncogenex Pharmaceuticals Inc | 2010-01-04 | 10.0 M | Exemption: 506 · Duration: One year or less · Revenue: No Revenues |
| CIK | Filing | 2011 - 2026 |
|---|---|---|
| [0000949858] | 10-K | |
| [0000949858] | 10-Q | |
| [0000949858] | 3 | |
| [0000949858] | 4 | |
| [0000949858] | 5 | |
| [0000949858] | 8-K | |
| [0000949858] | D | |
| [0000949858] | SC 13D | |
| [0000949858] | SC 13G |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Donnelly Craig
Stock Option (right to buy) · derivative
|
2026-01-28 | Grant | 180,000 | $0.00 | |
|
Stewart Richard Alistair
Stock Option (right to buy) · derivative
|
2026-01-28 | Grant | 645,000 | $0.00 | |
|
Rubinstein Mark Lawrence
Stock Option (right to buy) · derivative
|
2026-01-28 | Grant | 180,000 | $0.00 | |
|
Oki Mark K
Stock Option (right to buy) · derivative
|
2026-01-28 | Grant | 180,000 | $0.00 | |
|
Xinos Jaime
Stock Option (right to buy) · derivative
|
2026-01-28 | Grant | 180,000 | $0.00 | |
|
Wan Jerry
Stock Option (right to buy) · derivative
|
2026-01-28 | Grant | 70,300 | $0.00 | |
|
Atkisson Erik
Stock Option (right to buy) · derivative
|
2025-12-04 | Grant | 250,000 | $0.00 | |
|
Donnelly Craig
Stock Option (right to buy) · derivative
|
2025-10-01 | Grant | 50,000 | $0.00 | |
|
Common Stock
|
2025-09-18 | Sell | 129,501 | $2.92 | 378,143 |
|
Performance Restricted Stock Unit (PRSU) · derivative
|
2025-09-18 | Option exercise | 140,000 | $0.00 | |
|
Performance Restricted Stock Unit (PRSU) · derivative
|
2025-09-18 | Option exercise | 157,500 | $0.00 | |
|
Common Stock
|
2025-09-18 | Option exercise | 297,500 | $0.00 | |
|
Performance Restricted Stock Unit (PRSU) · derivative
|
2025-09-18 | Option exercise | 168,000 | $0.00 | |
|
Common Stock
|
2025-09-18 | Option exercise | 168,000 | $0.00 | |
|
Common Stock
|
2025-09-18 | Sell | 50,060 | $2.92 | 146,175 |
|
Performance Restricted Stock Unit (PRSU) · derivative
|
2025-09-04 | Option exercise | 24,500 | $0.00 | |
|
Performance Restricted Stock Unit · derivative
|
2025-09-04 | Grant | 157,500 | $0.00 | |
|
Performance Restricted Stock Unit · derivative
|
2025-09-04 | Grant | 140,000 | $0.00 | |
|
Performance Restricted Stock Unit (PRSU) · derivative
|
2025-09-04 | Option exercise | 26,000 | $0.00 | |
|
Performance Restricted Stock Unit (PRSU) · derivative
|
2025-09-04 | Option exercise | 84,000 | $0.00 | |
| showing 20 of 200 most recent transactions | |||||
| 13F Ownership Over Time | Holders | Shares Held |
|---|---|---|
| 2026-03-31 | 82 | 22,150,181 |
| 2025-12-31 | 78 | 23,451,945 |
| 2025-09-30 | 69 | 15,958,451 |
| 2025-06-30 | 68 | 26,580,642 |
| 2025-03-31 | 73 | 14,414,524 |
| 2024-12-31 | 71 | 16,432,548 |
| 2024-09-30 | 67 | 17,080,552 |
| 2024-06-30 | 61 | 19,628,564 |
| 2024-03-31 | 43 | 16,688,795 |
| 2023-12-31 | 32 | 2,787,193 |
| 2023-09-30 | 36 | 3,172,619 |
| 2023-06-30 | 41 | 3,766,932 |
| Form 13F Holdings | ||||
|---|---|---|---|---|
| Firm | Period | DFND | Voting | Shares |
| Simplify Asset Management Inc | [2026-06-30] | SOLE | 1,432,105 | 1,432,105 |
| Manchester Financial Inc | [2026-06-30] | SOLE | 0 | 67,177 |
| Members Wealth LLC | [2026-06-30] | SOLE | 0 | 66,763 |
| Windsor Capital Management LLC | [2026-06-30] | SOLE | 10,817 | 10,817 | Prev | Page 1 | Next |